What does "hemolytic child" mean?

Hemolytic disease of the newborn, medically known as erythroblastosis fetalis, is a condition caused by blood type incompatibility between the mother and her baby. When the mother and fetus have incompatible blood types, the mother's body may produce antibodies that cross the placenta into the fetal bloodstream, attacking and destroying the fetus's red blood cells, causing a hemolytic reaction.

The occurrence of hemolytic disease in newborns is associated with multiple factors, the most common being Rh blood group incompatibility and ABO blood group incompatibility. Rh incompatibility may occur when the mother is Rh-negative and the fetus is Rh-positive. ABO incompatibility is more likely when an O-type mother and an A- or B-type father conceive a child, increasing the risk of ABO incompatibility hemolytic disease.

Treatment for hemolytic disease in newborns typically includes phototherapy, drug therapy, and exchange transfusion. Phototherapy is suitable for infants with mild symptoms and works by reducing the levels of unconjugated bilirubin in the blood and serum. Drug therapy often involves medications such as dexamethasone and prednisone acetate, which suppress the infant's immune function to reduce red blood cell destruction. Exchange transfusion is used for infants with severe symptoms and directly treats the condition by removing bilirubin from the bloodstream.